AIN457

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

April 2, 2019

https://clinicaltrials.gov/ct2/show/NCT02607774?type=Intr&cond=Psoriasis&lupd_s=03%2F19%2F2019&lupd_d=14

Condition : Moderate to Severe Plaque Psoriasis

Interventions : Drug: Midazolam; Drug: AIN457

Sponsor : Novartis Pharmaceuticals

Completed

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

NCT02607774

Wed, 18 Nov 2015 12:00:00 EST

Last Update Posted: 04/02/19 08:12AM

March 11, 2019

https://clinicaltrials.gov/ct2/show/NCT03031782?type=Intr&cond=Psoriasis&lupd_s=02%2F25%2F2019&lupd_d=14

Conditions : Juvenile Psoriatic Arthritis; Enthesitis-related Arthritis

Interventions : Drug: AIN457; Other: Matched placebo

Sponsor : Novartis Pharmaceuticals

Recruiting

Secukinumab Safety and Efficacy in JPsA and ERA

NCT03031782

Thu, 26 Jan 2017 12:00:00 EST

Last Update Posted: 03/11/19 10:04AM